7 Factors to Choose a Biologics CDMO for mAbs
Selecting a contract development and manufacturing organization (CDMO) for monoclonal antibody manufacturing is one of the highest-stakes decisions a biopharma company makes. The wrong choice can delay clinical timelines, compromise regulatory submissions and disrupt patient supply. The right choice accelerates development, reduces risk and builds a foundation for commercial success.
Yet many companies approach CDMO selection by comparing brand names and capacity claims rather than evaluating the operational factors that actually determine program outcomes. This article outlines seven criteria that matter most when choosing a biologics CDMO for mAb programs—and how to assess them during due diligence.
1. End-to-End Capabilities from Cell Line to Commercial Supply
Monoclonal antibody manufacturing involves a complex sequence of interdependent steps: cell line development, upstream cell culture, downstream purification, formulation, fill/finish and stability testing. Each handoff between organizations introduces risk—delays, miscommunication and quality gaps.
A CDMO with integrated end-to-end capabilities can manage the entire process under a single quality system and project management structure. This reduces handoff risk and accelerates timelines by eliminating the coordination burden that comes with managing multiple vendors.
When evaluating end-to-end capabilities, look beyond marketing claims. Ask whether the CDMO performs cell line development (MCB/WCB) in-house, whether upstream and downstream operations are co-located and whether drug substance and drug product manufacturing share integrated quality systems.
AbbVie Contract Manufacturing offers comprehensive biologics development and manufacturing services including cell line development, upstream/downstream process development, cGMP manufacturing, analytical characterization, stability studies and regulatory support—all within a unified operational network.
2. Scale Flexibility Across Development Phases
mAb programs evolve. Early clinical batches may require 2,000L bioreactor runs; commercial supply may demand 12,000L capacity or multi-batch campaigns. A CDMO that cannot accommodate this range forces you to re-qualify a new partner mid-program—a costly and time-consuming disruption.
Evaluate whether the CDMO offers multiple bioreactor scales, both single-use and stainless steel options and the ability to support clinical through commercial volumes without requiring a site transfer. Geographic redundancy also matters: a global footprint provides supply chain resilience and regulatory flexibility for multi-market filings.
AbbVie's biologics manufacturing network includes 2,000L single-use bioreactors (SUBs) and 3,000L, 6,000L and 12,000L stainless steel equipment options across facilities in the US, Europe and Singapore—enabling scale-up without site changes.
3. Tech Transfer Expertise & Process Understanding
Tech transfer is where many CDMO relationships fail. A process that works in your development lab may behave differently at a new site with different equipment, raw materials and personnel. The CDMO's ability to anticipate and resolve these differences determines whether your transfer succeeds on the first attempt or requires multiple costly engineering runs.
Look for CDMOs with documented tech transfer methodologies, experience with similar modalities and a science and technology team that can apply modeling, simulation and process characterization to de-risk the transfer. Ask about their track record: how many transfers have they completed, and what percentage succeeded within the planned timeline and batch count?
AbbVie leverages predictive approaches including first-principles models, engineering calculations and simulations alongside experimental approaches such as process analytical technologies and small-scale equipment studies. This combination reduces the number of engineering runs required and builds confidence before commercial-scale execution.
4. Quality Systems & Regulatory Track Record
Regulatory agencies inspect CDMOs, and inspection outcomes directly affect your program. A warning letter or consent decree at your CDMO can delay your BLA or NDA filing by months or years. Quality culture is not a marketing phrase—it is a measurable operational characteristic.
During due diligence, request the CDMO's inspection history with FDA, EMA and other relevant agencies. Ask about their quality management system maturity, deviation and CAPA trends and how they handle investigations. A CDMO that has successfully supported multiple BLA and NDA filings brings regulatory intelligence that can strengthen your own submission.
AbbVie Contract Manufacturing operates within AbbVie's global quality organization, which has an exemplary audit and regulatory track record across products distributed to over 175 countries. This experience translates to regulatory guidance and support including filing strategies and global marketing approval expertise.
5. Analytical Capabilities & Method Development
Biologics require extensive analytical characterization to demonstrate identity, purity, potency and stability. A CDMO with limited analytical capabilities will either slow your program or force you to manage a separate analytical services provider—adding complexity and risk.
Evaluate the CDMO's analytical services portfolio: do they offer HPLC (SEC, IEX, affinity, reverse phase), host cell protein assays, electrophoresis methods (CE, IEF, SDS-PAGE), ELISA, peptide structure determination, oligosaccharide analysis and bioburden/endotoxin testing? Can they develop and validate methods in-house, or do they outsource critical testing?
AbbVie's integrated analytical services support the full spectrum of mAb characterization, from extended product characterization during development through release and stability testing for commercial supply. This integration ensures analytical methods transfer seamlessly alongside manufacturing processes.
6. Experience with Your Specific Modality
Not all mAbs are alike. Bispecific antibodies, fusion proteins and antibody-drug conjugates (ADCs) each present distinct manufacturing challenges. A CDMO with deep experience in your specific modality will anticipate problems that a generalist partner might miss.
Ask about the CDMO's portfolio of modalities: have they manufactured standard mAbs, bispecifics, trispecifics, fusion proteins and ADCs? What is their experience with high-concentration formulations, which are increasingly common for subcutaneous delivery? Do they have specialized capabilities such as conjugation suites for ADCs?
AbbVie's mammalian modality expertise spans monoclonal antibodies, fusion proteins, bispecific and trispecific antibodies and antibody-drug conjugates. For ADCs, AbbVie offers designated containment facilities capable of handling compounds with occupational exposure limits down to less than 10 ng/m³.
7. Partnership Model & Business Continuity
CDMO relationships often span a decade or more. The partner you choose today will be managing your commercial supply years from now. Evaluate not just current capabilities but the CDMO's business model, financial stability and commitment to the contract manufacturing business.
Embedded CDMOs—those operating within larger pharmaceutical companies—offer distinct advantages. They are not solely dependent on contract revenue to fund operations, which reduces the risk of over-commitment and under-delivery. They also benefit from the parent company's ongoing investment in facilities, technologies and quality systems.
AbbVie Contract Manufacturing operates as an embedded CMO within AbbVie's global operations network. This model provides access to AbbVie's extensive R&D and manufacturing expertise, ongoing capital investment and a quality organization that supports both AbbVie's own products and partner programs with equal rigor. AbbVie CMO has been recognized as a CMO Leadership Award winner for 12 consecutive years based on client satisfaction, performance and product delivery.
Making the Decision
CDMO selection is not a procurement exercise—it is a strategic partnership decision. The seven factors outlined above provide a framework for evaluating candidates based on operational capabilities rather than marketing claims.
The most successful CDMO relationships are built on transparency, aligned expectations and a shared commitment to patient outcomes. When both parties treat the program as if it were their own product, the partnership delivers results that neither could achieve alone.
To discuss how AbbVie Contract Manufacturing can support your mAb program, contact our team to start a conversation.